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In the present study we have analysed the regulation of pocket
protein expression and post-transcriptional modifications on cell
proliferation and differentiation, both in io and in itro. There
are marked changes in pocket protein levels during these tran-
sitions, the most striking differences being observed between
p130 and p107. The mechanisms responsible for regulating
pocket protein levels seem to be dependent on both cell type and
pocket protein, in addition to their dependence on the cell
growth status. Changes in retinoblastoma protein and p107
levels are independent of their state of phosphorylation.However,
whereas p130 phosphorylation to forms characteristic of
quiescent}differentiated cells results in the accumulation of p130
protein, phosphorylation of p130 to one or more forms charac-
teristic of cycling cells is accompanied by down-regulation of its
INTRODUCTION
The retinoblastoma family of pocket proteins, which comprises
retinoblastoma protein (pRB), p107 and p130, is believed to have
crucial roles in processes of cell proliferation and differentiation
[1–3]. Pocket protein function is associated with the regulation of
transcription factors belonging to the E2F family, which are
necessary for cell cycle progression. Pocket proteins form com-
plexes with E2Fs and repress the transcription of genes required
for cell cycle progression that contain E2F sites in their pro-
moters. It is widely accepted that the state of phosphorylation of
pocket proteins is responsible for regulating their interaction
with E2F proteins, and the phosphorylation of pocket proteins is
regulated in response to both positive and negative growth
signals. These signals converge on the family of cyclin}cyclin-
dependent kinase (CDK) holoenzymes, which are sequentially
activated throughout the cell cycle. Hyperphosphorylation of
pocket proteins by cyclin}CDKs in mid-G
"
results in the dis-
ruption of pocket protein}E2F complexes and the transcription
of E2F-dependent genes necessary for cell cycle progression
[1–3]. Therefore the availability of active cyclin}CDKs deter-
mines the amount of hypophosphorylated forms of each pocket
protein able to associate with E2F in proliferating cells. In non-
proliferating cells, G
"
}S cyclin}CDK holoenzymes are not active
and pocket proteins can therefore associate with E2Fs.
Abbreviations used: CDK, cyclin-dependent kinase ; DMEM, Dulbecco’s modified Eagle’s medium; EMSA, electromobility shift assay ; FBS, fetal bovine
serum; G-CSF, granulocyte colony-stimulating factor ; IL-3, interleukin 3 ; PH, partial hepatectomy; pRB, retinoblastoma protein ; VSMCs, vascular
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protein levels. We also show here that the phosphorylation status
and protein levels of p130 and p107 are regulated in io as in
cultured cells. In io, changes in p130 forms are correlated with
changes in E2F complexes. Moreover, the modulation of p130
and p107 status during cell differentiation in itro is consistent
with the patterns of protein expression and phosphorylation
status found in mouse tissues. Thus in addition to the direct
disruption of pocket protein}E2F complexes induced by
cyclin}cyclin-dependent kinase, the results we report here indicate
that the differential modulation of pocket protein levels con-
stitutes a major mechanism that regulates the pool of each
pocket protein that is accessible to E2F and}or other tran-
scription factors.
Each pocket protein has a preference for forming complexes
with specific E2F members at specific stages of the cell cycle. The
formation of specific pocket protein}E2F complexes is regulated,
at least in part, by the availability of specific E2F members.
Thus, whereas E2F-4 is characteristic of quiescent cells, E2F-1,
E2F-2 and E2F-3 are primarily transcribed from mid-G
"
[1,2].
Several reports suggest strongly that p130}E2F complexes have
a role during G
!
and in very early stages of the G
"
phase. p130
is the major pocket protein associated with E2F species in
quiescent cells such as human and rodent fibroblasts [4–8],
human T lymphocytes [9,10], terminally differentiated muscle
cells [11–14], neuronal PC19 cells [13] and melanocytes [15]. The
E2F partner of p130 has consistently been identified as E2F-4 in
the above-mentioned studies. Furthermore p130 accumulates
and is phosphorylated to specific forms that bind to E2F-4 when
cells exit from the cell cycle to quiescence [16]. p130}E2F
complexes accumulate when cells exit from the cell cycle, but are
scarce when cycling cells enter G
"
from mitosis, suggesting that




Although pRB has also been reported to form complexes with
E2F in differentiating cells [4], pRB seems to bind preferentially
to E2F in mid–late G
"
and S phases. Similarly, p107 forms
complexes with E2F predominantly in late G
"
and S phases, with
E2F-4 as its primary E2F partner. Transcription of the E2F-1
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, coinciding with the presence of p130}E2F-4 complexes,
which are found only before cyclin}CDK activation in mid-G
"
but not at later stages of the cell cycle [6,7,16]. Disruption of
p130}E2F-4 complexes on cyclin}CDK activation in mid-G
"
is
typically followed by formation of pRB}E2F-1 and p107}E2F-
4 complexes, although in certain cell types pRB}E2F-4 complexes
are also found [4,10]. In contrast with p130}E2F complexes, E2F
complexes containing pRB and p107 are detected during late G
"
and S phases. It has therefore been suggested that phos-
phorylation of pRB and p107 by cyclin}CDK is modulated in a
manner so that hyperphosphorylated and hypophosphorylated
forms are kept in balance and any required pool of hypo-
phosphorylated pRB or p107 able to interact with E2F will be
maintained during mid–late G
"
and S phases [1], thus allowing
the accurate differential transcriptional regulation of E2F-de-
pendent genes.
Although cyclin}CDK phosphorylation of pocket proteins
seems to be critical in regulating their interaction with E2F
proteins, the complex array of pocket protein}E2F interactions
observed during the cell cycle and cell cycle exit indicates that
there must be further mechanisms of pocket protein regulation in
addition to cyclin}CDK phosphorylation. Changes in p130 and
p107 levels have been occasionally correlated with changes in the
composition of E2F complexes in certain models [14]. Never-
theless regulation of pocket protein levels has rarely been
considered as a major mechanism controlling the activity of
pocket proteins. In the present study we have investigated this
possibility by analysing the pocket protein status in several
models of cell proliferation and differentiation. Our results, both
in itro and in io, indicate that pocket protein levels are
differently regulated during these processes and suggest that
phosphorylation and dephosphorylation events are co-ordinated
with modulation of pocket protein levels to regulate the amount
of each pocket protein available to associate with and repress
E2F and other cellular proteins at particular cellular stages.
EXPERIMENTAL
Cell cultures and tissues
T98G human glioblastoma cells and NIH-3T3 mouse fibroblasts
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
plus 10% (v}v) fetal bovine serum (FBS) supplemented with
penicillin}streptomycin. NIH-3T3 and T98G cells were syn-
chronized as described previously [16,17]. Asynchronously grow-
ing T98G cells were used as a control for the identification of the
different phosphorylated forms of pocket proteins in all Western
blot analyses. Skeletal muscle L6 (rat) and C2C12 (mice) cell
lines were grown as myoblasts in DMEM plus 20% (v}v) FBS
supplemented with penicillin}streptomycin until they reached
60–70% confluence. At that point, FBS was switched to 2%
(v}v) horse serum to induce differentiation. NFB cells, which are
derived from a clone of C2 cells and do not differentiate [18],
were grown similarly to C2C12 cells but after being switched to
2% horse serum they became quiescent. The murine interleukin
3 (IL-3)-dependent 32Dcl3 cell line was maintained in RPMI
1640 medium supplemented with 10% FBS and 10% (v}v)
WEHI3B-conditioned medium as a source of crude IL-3 [19].
For induction of differentiation, cells were centrifuged down and
resuspended in a medium containing 10% FBS and 15% (v}v)
CHO-conditioned medium as a source of granulocyte colony-
stimulating factor (G-CSF) [19]. On each of the following days,
smears were prepared from an aliquot of cell culture with a
Cytospin and were stained with May–Grunwald}Giemsa for
morphological analysis [19]. Primary vascular smooth-muscle
cells (VSMCs) were isolated essentially as described [20]. Primary
VSMCs and rat aorta A10 cells were maintained in DMEM
supplemented with 10% and with 20% fetal calf serum re-
spectively (growth medium). To render cells quiescent, cultures
were maintained for 3 days in DMEM supplemented with 0.5%
fetal calf serum. Quiescent primary VSMCs were serum re-
stimulated with growth medium. Protein extracts of VSMCs [21]
and A10 cells [22] were prepared as described previously.
Mouse tissueswere all obtained from the same animal sacrificed
by cervical dislocation. Tissues were dissected and immediately
frozen in liquid nitrogen and kept at ®80 °C until use. Tissue
extracts were prepared in lysis buffer [50 mM Tris}HCl
(pH 7.4)}0.1% (v}v) Triton X-100}5 mM EDTA}250 mM




}1 mM PMSF}10 lg}ml
leupeptin] with the aid of a tissue homogenizer (Polytron).
Electromobility shift assays (EMSAs)
EMSAs were performed by mixing either 8 lg of whole cell or
4 lg of nuclear protein extracts with 0.25 ng of c-$#P-end-labelled
double-stranded oligonucleotide probe containing the E2F-bind-
ing site of the E2 promoter in a total volume of 25 ll, as
described previously [23]. Where indicated, 4 ll of the specific
antibody were added. The sequences of the E2F oligonucleotides
used were 5«-ATTTAAGTTTCGCGCCCTTTCTCAA-3«
(wild-type) and 5«-ATTTAAGTTTCGATCCCTTTCTCAA-3«
(mutant). T98G whole-cell extracts for EMSA were prepared
in 5¬extraction buffer [100 mM Hepes (pH 7.4)}500 mM KCl}
5 mM MgCl
#
}0.5 mM EDTA}35% (v}v) glycerol}5 mM
NaF}1 mM dithiothreitol}100 lg}ml PMSF}5 lg}ml apro-
tinin}5 lg}ml leupeptin] as described previously [23]. Nuclei
from liver were obtained as described [24]. Nuclear extracts were
obtained by disrupting the nuclei by sonication in 150 ll of the
5¬extraction buffer (see above).
Rat and mouse 70% partial hepatectomy (PH)
Partial (70%) hepatectomy was performed on 8-week–old male
Sprague–Dawley rats and BALB}c mice as described previously
[25]. At the indicated time points, animals were killed and the
remnant liver tissue was harvested and flash-frozen in liquid
nitrogen.
Rat model of balloon injury
Acute endothelial denudation of the left common carotid artery
was performed essentially as described previously [26]. The right
uninjured carotid artery was used as control tissue. At the
indicated times after injury, rats were killed with sodium pento-
barbital (intraperitoneal injection, 100 mg}kg of body weight),
and both injured and uninjured common arteries were perfused
with saline and dissected free of surrounding tissue. Arteries were
frozen quickly in liquid nitrogen and stored at ®80 °C until the
preparation of the protein lysates as described previously [21].
Preparation of arteries and immunostaining for smooth-muscle
a-actin was performed as described previously [21].
Western blots and immunoprecipitation
Protein extracts of cells were prepared in lysis buffer (see above)
as described previously [27], with the exception of 32Dcl3 (see
below). The protein content of tissue and cell lysates was
measured by the method of Bradford (Bio-Rad) and 30–40 lg of
protein per sample was loaded on to SDS}PAGE gels (Protogel ;
National Diagnostics). Crude cell extracts from 32Dcl3 cells
were obtained by resuspending 10( cells in denaturing lysis buffer
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[33.3 mM glucose}33.3 mM Tris}HCl (pH 7.4)}6.66 mM
EDTA}2 M urea}2% (v}v) 2-mercaptoethanol}1% (w}v)





}4 lg}ml aprotinin}4 lg}ml leupeptin}4 lg}ml pep-
statin]. After sonication, extracts were incubated at 65 °C for
15 min and quantified by absorbance at 260 and 280 nm.
Polyacrylamide gels (6%, w}v) were used to analyse pRB-related
proteins and 10% (w}v) polyacrylamide gels to detect the levels
of the different cyclins. Proteins were transferred to PVDF
membranes and immunoblotted with specific antibodies [27].
p107 patterns in carotid samples were determined by immuno-
precipitation followed by Western blotting [27].
The antibodies used in these experiments were anti-p130
(SC-317), anti-p107 (SC-318), anti-pRB (SC-50), and anti-cyclin
D3 (SC-182) rabbit polyclonal antibodies and anti-cyclin D1
(SC-246) mouse monoclonal antibody from Santa Cruz Bio-
technology. Anti-pRB mouse monoclonal antibody (no. 14001A)
was from Pharmingen. Anti-cyclin A rabbit polyclonal anti-
body was a gift from Dr. Pines and anti-cyclin E rabbit
polyclonal antibody was a gift from Dr. Koff.
RESULTS
Pocket protein levels and phosphorylation status in mouse tissues
The effects of pocket proteins on cell growth are dependent on
cell type and several lines of evidence indicate that pocket
proteins fulfil an important role in the differentiation of certain
tissues [1,2]. We therefore sought first to compare the patterns of
pocket protein levels and phosphorylation status in io by
Western blotting in adult mouse tissues to ascertain whether
there is any specificity in their tissue distribution. Figure 1 shows
that the abundance of each pocket protein was highly variable
between the different tissues studied. The highest levels of each
pocket protein were detected in lung, spleen, thymus, and colon.
However, whereas p130 was still abundant in brain, liver,
Figure 1 Patterns of expression and phosphorylation of p130, p107 and
pRB in vivo in adult mouse tissues
Protein extract (40 lg) obtained from the indicated mouse tissues was resolved by SDS/PAGE
[6% (w/v) gel]. Proteins were transferred to PVDF membranes and immunoblotted with specific
antibodies (top panel, p130 ; middle panel, p107 ; bottom panel, pRB). Asynchronously growing
T98G glioblastoma cells were used as a control for identification of the different phosphorylated
forms of each pRB-family member (right-hand lane). Forms of each pocket protein are indicated
at the right (un, unphosphorylated p130). Tissues are indicated at the top as follows : Br, brain ;
Ki, kidney ; He, heart ; Li, liver ; Lu, lung ; SM, skeletal muscle ; SI, small intestine ; Sp, spleen ;
Th, thymus ; Pa, pancreas ; Co, colon ; Re, rectum ; St, stomach. A non-specific band co-
migrating with p130 form 3 was detected by the affinity-purified anti-p130 antibodies in skeletal
muscle tissue extracts by Western blot analysis. This cross-reacting protein, in contrast with
all p130 forms detected by Western blotting [16,17], was not immunoprecipitated by anti-p130
antibodies (results not shown) and probably corresponds to a highly abundant protein present
in skeletal muscle tissue.
Figure 2 Expression of G1/S cyclins in vivo in adult mouse tissues
Protein extract (40 lg) obtained from the indicated mouse tissues was resolved by SDS/PAGE
[10% (w/v) gel] and analysed by Western blotting as in Figure 1 by using specific antibodies
as indicated at the right [top panel, cyclin A ; second panel, cyclin E ; third panel, cyclin D1
(indicated faster mobility band) ; bottom panel, cyclin D3]. NIH-3T3 cells at different stages of
the cell cycle were used as a control for expression of cyclins (time points in hours after re-
stimulation are indicated at the top). Lane As, asynchronous cells. Tissues are indicated at the
top as in Figure 1.
pancreas, rectum and stomach, the levels of pRB and p107 in
these latter organs were comparatively low or even undetectable,
most notably regarding p107. With the exception of spleen and
thymus, the state of phosphorylation of pocket proteins is
characterized by the presence of underphosphorylated forms,
which are characteristic of non-proliferating cells. In particular,
p130 phosphorylated forms 1 and 2, characteristic of exit from
the cell cycle in cultured cell lines [16,17], are also detected in
adult tissues. These patterns are obviously reflecting that most
of the cells in most adult tissues are non-dividing, differentiated
cells. Because there is increasing evidence that p130 function is
involved in processes of cell cycle exit and differentiation (see
above), the high abundance of p130, particularly p130 forms 1
and 2, is consistent with the notion that it has a role in adult
differentiated tissues.
Spleen, thymus and colon are known to have a high cell
renewal rate and therefore contain a significant number of cells
progressing through the cell cycle [28]. This is consistent with the
pattern of phosphorylated forms shown in Figure 1: both
hyperphosphorylated pRB and p107 are present. Interestingly,
very low levels of p130 form 3 (compared with the high levels of
p130 forms 1 and 2) are detected in these tissues where hyper-
phosphorylated forms of pRB and p107 account for an important
portion of total pRB and p107 proteins respectively (Figure 1;
compare lanes Sp and Th). We have previously shown that when
quiescent cells enter the cell cycle and progress through G
"
, p130
is phosphorylated to form 3 and this is followed by down-
regulation of p130 protein levels [16,17]. It is therefore con-
ceivable that apart from abrogating p130}E2F interaction [16],
phosphorylation to p130 form 3 triggers its down-regulation.
Because even in the tissues with high cell renewal most of the cells
are in G
!
, and therefore contain p130 forms 1 and 2, it would be
expected that very low levels of p130 form 3, if any, contributed
by the cycling cells would be detected.
Because G
"
}S cyclin}CDK holoenzymes are most probably
the kinase activities phosphorylating pocket proteins during
progression through the cell cycle, we analysed the expression of
cyclins in mouse tissues to ascertain whether their expression is
consistent with the detection of low levels of p130 form 3 and
hyperphosphorylated pRB and p107 (Figure 2). Western blot
analysis was performed with the same protein extracts as used for
Figure 1. The expression of these proteins was also analysed in
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protein lysates of NIH-3T3 cells progressing synchronously
through G
"
as controls. As expected, expression of cyclins E and
A was detected only in tissues of high cell renewal, spleen and
thymus, where hyperphosphorylated pocket proteins were also
present. In contrast, expression of cyclin D1 and D3 was also
detected in tissues in which hyperphosphorylated forms of pocket
proteins were not detected. Furthermore it is important to note
that the presence of p130 forms 1 and 2 did not seem to be
correlated with the expression of any particular cyclin.
Regulation of pocket proteins during differentiation
p130 seems to be the major pocket protein in E2F complexes
during various differentiation programmes [11–15]. Our present
results show that p130 forms 1 and 2 are the major forms of p130
in all adult mouse tissues analysed. Moreover, p130 is relatively
abundant in some tissues in which the levels of pRB and p107 are
low when compared to their respective levels in other tissues
(Figure 1; compare, for instance, rectum and colon). Because
many of these tissues are composed mostly of differentiated cells,
these results suggest that there is differential regulation between
pocket proteins in processes of cell differentiation. To evaluate
such differences, we sought to analyse in detail two well-
characterizedmodels of cell differentiation in itro : differentiation
of mouse and rat myoblasts into myotubes and differentiation of
mouse myeloid precursors along the granulocyte lineage.
Skeletal muscle differentiation in vitro
Studies on skeletal muscle cell lines have shown that, whereas
undifferentiated myoblasts mostly contain p107}E2F complexes,
and to a minor extent p130}E2F complexes, differentiation into
myotubes results in the primary presence of p130}E2F complexes
[11–14]. It has also been suggested that changes in p130 and p107
levels were involved in the formation of these E2F complexes
[14]. Therefore we sought to analyse in detail the patterns of
expression and phosphorylation of p130 and p107 proteins
during skeletal muscle cell differentiation of rat L6 and mouse
C2C12 cells by Western blotting.
Both L6 and C2C12 proliferating myoblasts contained a
pattern of p130 forms (unphosphorylated protein and phos-
phorylated forms 1, 2 and 3) similar to the pattern of phos-
phorylation of exponentially growing, asynchronous glio-
blastoma human T98G cells (compare lane 0 of Figure 3 with
lane T98G in Figure 1). However, placing either cell line in
differentiation medium resulted in the rapid disappearance of
p130 form 3 and a striking increase in the levels of phosphorylated
p130 forms 1 and 2. This is in contrast with previous studies,
which did not detect the appearance of these phosphorylated
forms of p130 probably because of technical differences in the
analysis. In contrast, p107 was present at high levels in pro-
liferating myoblasts as both hyperphosphorylated and hypo-
phosphorylated forms, its levels dropped markedly as a result of
the differentiating transition, which is in agreement with the
results reported by Kiess et al. [14] with L6 cells. Because
p107}E2F complexes are not found in differentiated myotubes
(see [11,13,14]), hypophosphorylation of p107 induced by cell
cycle exit does not imply the formation of p107}E2F complexes,
but rather the decrease in p107 levels observed in Figure 3 seems
to prevent the formation of these complexes. In contrast, the
increase in the protein levels of p130 forms 1 and 2, which are the
only phosphorylated forms of p130 that bind to E2F-4 in io
[16], is an event that might explain the abundance of p130}E2F
observed in differentiated myotubes (see [11–14]). In conclusion,
opposite changes in levels of p130 and p107 are correlated in a
subtle manner with the changes in the composition of E2F
complexes reported earlier, and this differential regulation might
be sufficient to account for the composition of these pocket
protein}E2F complexes.
Interestingly, levels of p107 decrease during the differentiation
process in an independent manner with respect to its state of
phosphorylation: hyperphosphorylated and hypophosphory-
lated p107 are down-regulated to the same extent, this effect
being more apparent in L6 cells (Figure 3B). However, up-
regulation of p130 protein levels during skeletal muscle myo-
genesis takes place exclusively in p130 forms 1 and 2 in both cell
lines, suggesting that the phosphorylation state of p130 is related
to the regulation of its protein levels (see the Discussion section).
In this respect it is interesting to note that the kinase activities
responsible for phosphorylating p130 to forms 1 and 2 are active
in muscle cells that are irreversibly exiting from the cell cycle to
terminal differentiation.
It has been shown previously that cell cycle withdrawal
precedes phenotypic differentiation and cell fusion of C2C12
cells [29]. We therefore next sought to examine whether the
regulation of phosphorylation of p130 during skeletal myogenesis
is associated with exit from the cell cycle or with differentiation.
To this end we used a differentiation-deficient variant of C2 cells,
NFB cells, which were obtained after mutagenesis of C2 cells and
selection for defective differentiation [18]. NFB and C2C12
proliferating myoblasts were harvested at different time points
after placing them in differentiation medium (Figure 3C) and
p130 patterns were analysed by Western blotting. As shown in
Figure 3(D), the patterns of phosphorylation of p130 in quiescent
undifferentiated NFB cells and quiescent C2C12 differentiated
myotubes (Figure 3C) were indistinguishable after 1 day of
incubation in differentiation medium. These results indicate that
accumulation of p130 forms 1 and 2 occurs during exit from the
cell cycle before differentiation and fusion of skeletal myoblasts.
G-CSF-mediated granulocytic differentiation of 32Dcl3 cells
32Dcl3 cells are non-tumorigenic diploid cells derived from
normal mouse bone marrow that are dependent on IL-3 for
growth and survival. G-CSF stimulates the terminal differen-
tiation of 32Dcl3 cells into neutrophilic granulocytes [19,30].
When 32Dcl3 cells were placed in G-CSF-containing medium,
they proliferated for the first 4–6 days and then exited from the
cell cycle simultaneously with the appearance of mature forms of
the granulocytic lineage (Figure 4A). By days 9–14, the entire
population of cells was terminally differentiated to meta-
myelocytes and granulocytes (Figure 4A) [19].
32Dcl3 cells were induced to differentiate in the presence of G-
CSF and processed for Western blotting and flow cytometric
analysis and May–Grunwald}Giemsa staining. Figure 4(B)
shows that p130 was consistently present as a mixture of
phosphorylated forms resembling the patterns of some cells
growing asynchronously during the proliferative phase (lanes
12 h to 2 d). By day 4, p130 form 3 was progressively replaced by
form 2 and form 1 (Figure 4B, lane 4). p130 forms 1 and 2
accumulated between days 4 and 8 concomitantly with the arrest
of cells with a G
"
DNA content and with the appearance of cells
at different stages of granulocytic differentiation, including
myelocytes, metamyelocytes and few mature granulocytes
(Figures 4A and 4B). pRB was present in its hypophosphorylated
and hyperphosphorylated forms during the proliferation phase;
the hyperphosphorylated forms disappeared at the same time as
cell cycle exiting and the accumulation of p130 forms 1 and 2
(Figure 4B). In contrast, hyperphosphorylated p107 was the
major form of p107 during the proliferative phase, and its levels
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Figure 3 Changes in the phosphorylation status and levels of p130 and p107 during cell cycle exit and myogenesis in skeletal muscle
Skeletal muscle L6 (rat) and C2C12 (mouse) cells were grown as myoblasts until they reached 60–70% confluence. At that point, induction of differentiation resulted in the fusion of cells to form
multinucleated myotubes (see the Experimental section). NFB cells, which are derived from a clone of C2 cells, became quiescent after exiting from the cell cycle, but were unable to differentiate
(see the text). Protein extract (30 lg) obtained from C2C12 (A) or L6 (B) cells harvested at different time points after induction of differentiation was resolved by SDS/PAGE [6% (w/v) gel] and
immunoblotted with specific antibodies (upper panel, p130 ; lower panel, p107) as in Figure 1. The different forms of each pocket protein are indicated at the left. (C) Comparison of the morphological
changes induced in NFB and C2C12 cells by placing them in differentiation medium. C2C12 and NFB cells growing exponentially (labelled P) show the same morphology, but once they are induced
to exit from the cell cycle C2C12 cells differentiate to myotubes, whereas NFB cells become quiescent but do not differentiate into myotubes (days in the differentiation medium are indicated).
(D) Protein extract (30 lg) obtained from NFB or C2C12 cells growing exponentially (first lane), at 60% confluence (second lane) and at 1, 3 or 6 days after the cells were placed in differentiation
medium, was resolved as in (A) and immunoblotted with anti-p130 antibodies.
Figure 4 Changes in phosphorylation patterns and protein levels of p130, p107 and pRb during myeloid differentiation
(A) May–Grunwald/Giemsa staining of 32Dcl3 cells undergoing G-CSF-mediated differentiation. (B) Protein extract (60 lg) obtained from G-CSF-treated 32Dcl3 cells at different time points of
granulocytic differentiation (see the Experimental section) was resolved by SDS/PAGE [6% (w/v) gel] and immunoblotted as in Figure 1 (top panel, p130 ; middle panel, p107 ; bottom panel, pRb).
Asynchronously growing T98G glioblastoma cells were used as a control for the identification of different forms of pRb-family proteins (left-hand and right-hand lanes). Forms of each pocket protein
are indicated at the right. The percentage of cells at each phase of the cell cycle is indicated at the bottom. The lot of affinity-purified anti-p130 antibodies used in this Western blot cross-reacted
with p107, as indicated in the p130 panel.
decreased markedly by day 4 without significant accumulation of
hypophosphorylated p107. In conclusion, pocket protein levels
are again shown to be differentially regulated during cell diffe-
rentiation. The pattern of p130 protein levels and the presence of
p130 phosphorylated forms 1 and 2 are consistent with a role
for p130 during this differentiation process.
650 J. Garriga and others
Figure 5 Changes in vivo of the phosphorylation status and protein levels
of p130 and p107 in regenerating liver in mouse and rat
(A) Upper panel : 40 lg of protein extract obtained from regenerating mouse (lanes 1–6) and
rat (lanes 8–13) livers at different time points after PH (see the Experimental section) was
resolved in SDS/PAGE [6% (w/v) gel] and immunoblotted as in Figure 1 with specific
antibodies. Asynchronously growing T98G glioblastoma cells were used as a control for the
identification of the different phosphorylated forms of p130 (lane T). Lower panel : p107 patterns
in samples obtained after PH were determined by immunoprecipitation followed by Western
blotting with anti-p107 antibodies. Protein (300 lg) for each time point was immunoprecipitated
with anti-p107 antibodies. Immunoprecipitates were resolved by SDS/PAGE [6% (w/v) gel] and
immunoblotted with anti-p107 antibodies as in Figure 1. Time points after hepatectomy are
indicated in hours at the top. (B, C) EMSAs were performed as described in the Experimental
section. The time points, addition of competitor oligonucleotide and antibodies used for the
supershifts are indicted at the top. E2F species are indicated. (B) E2F–DNA-binding activities
during liver regeneration. (C) Comparison of E2F species from quiescent and proliferating T98G
cells and mouse liver nuclei.
Regulation of pocket protein levels during models of cell
proliferation in vivo
p130 and p107 undergo changes in protein levels and phos-
phorylation state in cultured quiescent cells and cells progressing
through the cell cycle [16,17,31]. To ascertain whether a similar
modulation of p130 and p107 proteins also takes place during
cell cycle re-entry of cells differentiated in io, we analysed the
p130 and p107 patterns during tissue regeneration in io after
PH in the rat and mouse, and after acute arterial injury in the rat.
Rat and mouse models of liver regeneration after 70% PH
Rat and mouse liver regeneration after PH are two well-
characterized models of cell proliferation in io. The decrease in
liver mass resulting from surgical hepatectomy triggers the
synchronized proliferation of hepatocytes in the remaining lobes,
resulting in the restoration of liver mass and function. Entrance
of hepatocytes to the cell cycle can be monitored by peaks of
DNA synthesis after PH at approx. 24 h in the rat and 36 h in the
mouse and by timed synthesis of cyclins and CDKs that results
in the activation of cyclin}CDK holoenzymes [32–34]. Protein
extracts obtained from the livers at different time points after
PH were prepared and analysed by Western blotting. Both
mouse and rat adult livers contained the unphosphorylated
and the phosphorylated forms 1 and 2 of p130 (Figure 1, and
Figure 5A, 0 h), which is the G
!
pattern consistent with the
differentiated state of adult hepatocytes. As expected, PH caused
the phosphorylation of p130 to form 3 (Figure 5A, 24–48 h in
the mouse and 12–36 h in the rat) during periods before and
simultaneous with the entrance of hepatocytes into the S phase
[33,34]. However, p130 forms 1 and 2 did not disappear, nor did
p130 total protein levels seem to diminish on G
"
}S-phase
progression, which is in contrast with previous results obtained
with cultured cells. This result was expected because the entire
population of hepatocytes does not enter the cell cycle during the
first proliferative wave after PH; thus a residual proportion of
hepatocytes will account for the presence of p130 forms 1 and 2.
Moreover because most regenerating hepatocytes divide only
once [35], cell cycle progression during liver regeneration seems
to be similar to that in culture conditions in itro described
previously, in which cells progress through S and G
#
}M phases
in the absence of serum, in which case the next exit from mitosis
leads to a direct entrance into G
!
[16]. In neither case does down-
regulation of p130 form 3 occur in the S phase.
In contrast with p130, the analysis of the expression and
phosphorylation status of p107 showed almost undetectable
levels of p107 in adult liver (Figures 1 and 5A). Regeneration
after PH resulted in an increase in p107 expression and in the
appearance of hyperphosphorylated p107, correlated with the
presence of p130 form 3, suggesting that similar G
"
cyclin}CDK
holoenzymes target these pocket proteins co-ordinately. As
observed in cells grown in itro, p107 expression and post-
translational modifications were observed mainly in cycling cells.
p107 levels were again shown to be tightly regulated during a
proliferative process in io ; interestingly, this regulation seems
to be independent of the state of phosphorylation of p107.
We also analysed E2F–DNA-binding activities in nuclear
protein extracts of adult and regenerating mouse livers by EMSA.
Adult liver nuclei contained two major E2F complexes (Figure
5B, lane 4). The fastest-migrating E2F complex contained E2F-
4, whereas the slowest contained p130, as demonstrated by
supershift of these complexes with anti-E2F-4 and anti-p130
antibodies respectively (Figure 5B; compare lane 4 with lanes 9
and 15). Marked changes in E2F–DNA-binding activities were
detectable as early as 12 h after hepatectomy. The p130}E2F
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Figure 6 p130 expression in different models in vivo and in vitro of smooth-muscle cell cycle re-entry
(A) Smooth-muscle a-actin immunohistochemical staining of uninjured rat carotid artery (left panel) and 2 weeks after balloon angioplasty (right panel). In this model, injury-induced VSMC
proliferation and migration results in intimal lesion formation within 2 weeks of angioplasty. Cross-sections of arteries were immunostained with mouse anti-(smooth-muscle a-actin) monoclonal
antibody as described previously [21]. Black and white arrowheads point to the external and internal elastic laminae respectively. Abbreviations : adv, adventitia ; med, media ; int, intimal lesion.
Magnification ¬20. (B) Protein lysate (40 lg) from control (C) and balloon-injured rat carotid arteries at different times (2 days and 1 and 2 weeks) after angioplasty was analysed by Western
blotting with specific anti-p130 and anti-p107 antibodies as in Figure 1. Protein forms are indicated at the right. (C) Primary cultures of rat aorta VSMCs were maintained at subconfluence in
growth medium [proliferating (P)], serum-starved for 3 days [quiescent (Q)] or serum-starved for 3 days and re-stimulated for 1 day with growth medium (RS). Protein extracts were analysed by
Western blotting as in Figure 1 with anti-p130 antibodies. Protein forms are indicated at the right. (D) Quiescent rat aorta A10 cells were serum-starved (0) and re-stimulated with FBS (see the
Experimental section). Cells were harvested at the indicated time points (in hours), and protein extracts were analysed by Western blotting as in Figure 1 with the use of specific anti-p130 antibodies.
Protein forms are indicated at the right.
complex disappeared and the E2F-4 complex seemed to be
down-regulated initially and up-regulated to maximal levels by
36 h, coinciding with the S phase (Figure 5B; compare lanes
5–7). A new E2F complex not containing E2F-4 was detected at
that time and disappeared by 72 h, coinciding with the re-
appearance of the p130}E2F species and cell cycle exit (Figure
5B; compare lanes 7 and 8). Other E2F complexes not containing
p130 were detected between 12 and 36 h. Anti-p107 antibodies
did not supershift any of these complexes, suggesting that
E2F}p107 complexes are absent or scarce. Interestingly, anti-
bodies against E2F-4 supershifted most E2F complexes but did
not supershift most of the E2F complex containing p130 in
quiescent liver nuclei (Figure 5B; compare lane 4 with lanes 9
and 15, and lane 8 with lanes 13 and 19). This is in contrast with
similar experiments performed with quiescent human T98G cells.
Two major E2F complexes were detected in serum-starved T98G
cells, co-migrating with those detected in nuclei from adult liver
(Figure 5C; compare lanes 2 and 11). However, whereas the
slowest E2F complex detected in quiescent T98G cells contained
both p130 and E2F-4 (Figure 5C; compare lanes 2 and 3 with
lanes 5 and 6 and lanes 8 and 9), the co-migrating complex in
liver nuclei was not supershifted by the anti-E2F-4 antibody
(Figure 5C; compare lanes 11–13). Thus these experiments seem
to indicate that p130 associates with an E2F family member
other than E2F-4 in mouse adult liver.
Rat acute arterial injury
During homoeostasis, VSMCs display a differentiated phenotype
and are quiescent. However, in contrast with skeletal and cardiac
myocytes, VSMCs can re-enter the cell cycle after appropriate
stimuli [36]. The modulation of the expression and phosphory-
lation of p130 and p107 was examined after balloon angioplasty
in the rat carotid artery. In this model, balloon denudation
triggers a rapid proliferative response of VSMCs in the media,
followed by a second proliferative wave within the intimal lesion
[37,38], which leads to intimal lesion formation (Figure 6A). It
has been shown previously that the thymidine index in the media
peaks approx. 2 days after angioplasty [26], coincident with the
induction of CDK2 and its regulatory subunits, cyclins E and A
[21]. Protein lysates were prepared at different time points after
angioplasty and examined by Western blot analysis. As shown in
Figure 6(B), control adult rat carotid arteries exhibited the
pattern of p130 forms characteristic of quiescent cells : unphos-
phorylated and phosphorylated p130 forms 1 and 2. These forms
were markedly down-regulated 2 days after angioplasty and low
levels of p130 form 3 were detectable at this time point. As
occurred after PH (see above), low levels of p130 forms 1 and 2
were also observed, coinciding with VSMC proliferation in io.
This could be explained by the presence of non-proliferating cells
in the samples, as occurred after PH, owing to poor cell cycle
synchrony because of the spatial and temporal dependence in the
activation of the different smooth-muscle cell layers. At 1 week
after angioplasty, the levels of p130 forms 1 and 2 returned to
control levels. Nevertheless the most significant finding was
again the abrupt up-regulation of p107 levels that were seen
during the proliferative activation, in a manner similar to the
effects induced on p107 after PH (Figures 5B and 6B). The
increase in p107 levels also seemed to occur independently of
p107 hyperphosphorylation. These findings are therefore con-
sistent with p107’s expression and phosphorylation being re-
stricted to cycling VSMCs.
Because the modulation of p130 was less apparent in the
vascular regeneration model, probably owing to the hetero-
geneous synchrony in proliferation of the different smooth-
muscle cell layers, we analysed p130 by Western blotting during
the synchronous proliferation of primary rat aortic VSMCs.
These cells display a differentiated, quiescent phenotype under
serum starvation and can re-enter the cell cycle after appropriate
stimuli. As shown in Figure 6(C), asynchronously growing
primary VSMCs showed low levels of hyperphosphorylated p130
form 3 together with higher levels of forms 1 and 2; this could be
explained by the fact that a portion of the cells in these cultures
might not have been proliferating, owing to contact inhibition.
When these cells were made quiescent, p130 form 3 consistently
disappeared, coinciding with a slight accumulation of p130 forms
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1 and 2. Re-entry of these cells into the cell cycle resulted in the
down-regulation of p130 forms 1 and 2 and the reappearance of
p130 form 3, although at very low levels ; this could be explained
by the fact that a proportion of the cell population did not re-
enter the cell cycle. It is also conceivable that p130 form 3 is
found in vascular aortic cells in such low levels because this form
is extremely unstable in these cells and is therefore degraded very
early after phosphorylation in mid-G
"
. Finally, the modulation
of p130 was also analysed in serum-starved and re-stimulated rat
aorta A10 smooth-muscle cells (Figure 6D). p130 form 3 was




, whereas the levels
of p130 forms 1 and 2 decreased. The clear detection of
phosphorylation of p130 to form 3 is consistent with a larger
number of cells progressing synchronously through G
"
in this
culture model in itro (see above).
DISCUSSION
In the present study, protein levels and the phosphorylation of
pocket proteins are shown to be tightly and differently regulated
in various models of cell proliferation and differentiation. Three
main conclusions are derived from the present study. First,
distinct changes in pocket protein levels are shown to occur in a
conserved fashion in different models, and this differential
regulation parallels some of the changes in the composition of
E2F complexes. Secondly, phosphorylation events and the ac-
cumulation of p130 characteristic of departure from the cell cycle
[16] are shown here to be conserved when transit to G
!
also
involves terminal differentiation. Interestingly, whereas p130
phosphorylation status seems to be coupled to the levels of p130
protein, the phosphorylation status of pRB and p107 does not.
Thirdly, p130 and p107 levels and phosphorylation status are
regulated in io as in cultured cells. The modulation of p130
phosphorylation status is correlated with changes in E2F ac-
tivities in io.
Differential regulation of pocket protein levels
The differential regulation of pocket protein levels shown here
might have direct implications for our understanding of the
regulation of the repressing activity of pocket proteins on E2F-
dependent transcription, and in particular the repression of E2F-
4 by p130 and p107. The up-regulation of p130 and the down-
regulation of p107 levels during differentiation shown here are a
plausible explanation of the fact that the differentiation in itro
of some cell types, including muscle cells, involves a change from
p107}E2F-4 complexes in proliferating cells to p130}E2F-4
complexes in differentiated cells [11–15]. Similarly, changes in
p130 and p107 levels observed previously during the cell cycle
progression of cell lines in itro [16,17,31] are reproduced here in
models of tissue regeneration in io (Figures 5 and 6). This
might also explain why p130}E2F-4 complexes are the only E2F
complexes found in a number of quiescent cells, and why
progression through the G
"
phase involves a complete shift of
E2F-4 from p130 to p107 and the pRB complexes [4,5,9,10].
Therefore, although cyclin}CDK phosphorylation regulates the
interaction of E2F-4 with p130 and p107, it is not sufficient to
explain the changes in the composition of E2F-4 complexes
during the processes studied. Instead, the regulation of p130 and
p107 levels is a probable mechanism of regulation of the
composition of E2F-4 complexes in particular cellular stages.
The mechanisms underlying the regulation of p130 and p107
levels are clearly distinct. Present and previous results suggest
that specific phosphorylation events of p130 affect the stability of
the protein [1,2]. First, phosphorylation of p130 to the cell cycle
exit-specific forms 1 and 2 is correlated with the accumulation of
p130 protein in the cell, but cyclin}CDK phosphorylation to
form 3 in mid-G
"
phase is followed by marked down-regulation
of the p130 protein [6,16,17]. Secondly, labelling experiments in
io with either [$&S]methionine or [$#P]P
i
showed that radio-
activity is poorly incorporated in p130 forms 1 and 2 of quiescent
cells but is much more efficiently incorporated in p130 form 3 of
proliferating cells [14,17]. Interestingly, p130 form 2 was not
labelled in these experiments. Therefore both the synthesis and
the phosphorylation turnover of p130 forms 1 and 2 are much
slower than the turnover of p130 form 3. Consistent with this, it
is conceivable that the phosphorylation of p130 to forms 1 and
2 results in the stabilization of p130, therefore requiring a slower
turnover to maintain the high levels of forms 1 and 2 present in
quiescent cells. This model is also consistent with the low rate of
synthesis of p130 detected in differentiated compared with
proliferating C2C12 cells [13] and with a recent report showing
that steady-state levels of p130 transcripts are not regulated
during differentiation [39]. This possibility is particularly inte-
resting because it has been shown that p130 stabilizes E2F-4,
protecting it from degradation by the ubiquitin proteasome
machinery [40]. Thus the stabilization of p130 by cell cycle exit-
specific phosphorylation would in turn result in the accumulation






p107 is hyperphosphorylated by cyclin}CDKs to a form with
an electrophoretic mobility slower than the hypophosphorylated
form [31]. In contrast with p130, the state of phosphorylation of
p107 seems to be independent of changes in its protein levels, as
seen in the present study. Moreover it does not undergo the cell
cycle exit-induced phosphorylation characteristic of p130. Inte-
restingly, the p107 gene promoter has been shown to contain two
E2F sites that can drive the transcription of a reporter gene fused
to this promoter, and this promoter can be repressed by pocket
proteins [44]. This result suggests that transcription of p107 is, at
least in part, under E2F control and probably regulated during
the cell cycle. It is thus tempting to speculate not only that the
disruption of p130}E2F-4 complexes in mid-G
"
results in the
transcription of E2F-1 [7], but that either active free E2F-4 or the
newly synthesized E2F-1 activates the transcription of p107.
Further experiments are required to test this possibility.
Apart from the differential regulation of pocket protein levels,
two points regarding the regulation of p130 during both cell
differentiation and cell cycle re-entry in io deserve further
discussion.
Regulation of p130 during differentiation
The behaviour of p130 forms during differentiation is in striking
contrast with the changes observed for the p107 protein, and all
protein patterns are consistent with the profiles of these proteins
in mouse tissues (see above). The modulation of the phos-
phorylation and levels of p130 during skeletal muscle diffe-
rentiation as well as during granulocytic differentiation of 32Dcl3
cells is consistent with our previous analysis of p130 regulation
in cells exiting from the cell cycle to quiescence [16]. p130 form
3 is clearly detectable in proliferating C2C12 and L6 myoblasts,
and in the initial proliferative phase induced by G-CSF in 32Dcl3
cells (Figures 3 and 4). In both differentiation models, the
accumulation of p130 forms 1 and 2 (which are phosphorylated
forms) correlates with growth arrest and the initiation of terminal
differentiation. High levels of these forms are maintained in
terminally differentiated myotubes, consistent with a role for
p130 in the maintenance of this differentiated state. Interestingly,
it has been shown that the E2F complexes from quiescent and
differentiated cells, which contain p130 as a major associated
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pRB-related protein, can be distinguished [11,13,15] : whereas in
differentiated C2 cells there is a single E2F complex that contains
p130, in the C2 differentiation-defective derived cell line NFB,
there are various E2F activities [11]. A comparison of the protein
levels and phosphorylation status of p130 in differentiated C2C12
cells and quiescent NFB cells did not reveal any marked
difference. However, we cannot exclude the possibility that
although the p130 phosphorylated forms of quiescent undiffe-
rentiated NFB and differentiated C2C12 muscle cells co-migrate,
they might be phosphorylated at different sites. A definitive
answer will require the identification of the phosphorylation sites
on p130 after exit from cell cycle.
Modulation of the phosphorylation status of p130 in models in
vivo of cellular proliferation
The extremely low levels of p130 form 3 in mouse tissues
prompted us to analyse whether its absence was correlated with
the fact that most of the cells in these tissues were in G
!
.
Phosphorylation of p130 to form 3 in livers after PH occurred at
a time consistent with hepatic cells being in G
"
, before the peak
of DNA synthesis and coinciding with the expression and
activation of cyclin D1 [25]. Therefore, although the patterns of
expression of G
"
cyclins and CDKs might vary significantly
between different mammalian species during hepatic regeneration
[25], the phosphorylation of p130 and p107 seems to be similarly
regulated during both liver regeneration and cells grown in
culture, and our results are consistent with similar cyclin}CDK
holoenzymes targeting pocket proteins co-ordinately. In ad-
dition, the disruption and reappearance of p130}E2F complexes
during hepatic proliferation and differentiation in io is con-
sistent with changes on the phosphorylation status of p130.
Although E2F complexes have been analysed occasionally in
adult mammalian tissues [13,45], to the best of our knowledge
this is the first report describing the regulation of p130}E2F
complexes in a proliferative process in io.
By using the rat carotid model of angioplasty it has been
shown the temporal and spatial correlation between injury-
induced VSMC proliferation and the expression of CDK2 and
cyclins A and E [21]. Acute arterial injury results in the down-
regulation of p130 within 8 h (results not shown) and several
days after injury; however, p130 form 3 is hardly detectable at
any time. One possibility is that p130 form 3 might be extremely
unstable in proliferating VSMCs and is therefore degraded very
early after phosphorylation in mid-G
"
, which is in agreement
with the down-regulation of p130 form 3 from mid-G
"
to mitosis
[16,17] and with the low levels of p130 in some cell lines growing
exponentially [6]. In addition, different waves of proliferation in
the media and intima after angioplasty [26] might partly mask
the presence of p130 form 3 owing to the high levels of p130
forms 1 and 2 in quiescent cells. Serum re-stimulation of primary
rat VSMCs and rat aorta A10 cells (Figures 6C and 6D) resulted
in detectable levels of p130 form 3. As mentioned above, the
regulation of p107 levels is in striking contrast with that of p130.
The opposite regulation of these two proteins in io further
highlights their distinguishable functions.
As regards p130, the results reported here demonstrate that its
regulation is highly conserved during the mammalian cell cycle,
as well as the exit from the cell cycle to differentiation, both
in io and in itro. Phosphorylation of p130 during the exit
from the cell cycle might have a crucial role in regulating the
accumulation of p130, thus allowing the accumulation of
p130}E2F transcriptional repressors of growth-regulatory genes.
Interestingly, the fact that cell cycle exit-induced phosphorylation
of p130 to forms 1 and 2 is conserved after cell differentiation
indicates that the cell cycle exit-induced kinase(s) targeting p130
at this stage are active in differentiating cells.
We thank John Gibas for performing the flow cytometric analysis, Michelle Akiko for
technical assistance on the characterization of 32Dcl3 cells, Cory Ahonen and Brenda
Rieland for excellent technical assistance with mouse and rat liver hepatectomies,
Kevin Krasinski for excellent technical assistance with the balloon angioplasty
procedure, Matilde Parren4 o for critical reading of the manuscript, and Jonathan Pines
and Andrew Koff for antibodies. J.G. was initially supported by a CIRIT fellowship
(Generalitat de Catalunya), J.G. and X.M. were supported by a fellowship from
Direccio! n General de Investigacio! n Cientı!fica y Te! cnica (Ministerio de Educacio! n y
Ciencia, Spain), A. L. was supported by a Lady Tata fellowship, and J.H.A. was
supported by a grant from the American Liver Foundation. This work was supported
by an Institutional ACS grant no. ACS IRG-204, a Wendy Will Case Cancer Fund grant
and a grant from the National Institute of General Medical Sciences, NIH (GM54894)
(X.G.).
REFERENCES
1 Mayol, X. and Gran4 a, X. (1998) Frontiers Biosci. 3, 11–24
2 Mayol, X. and Gran4 a, X. (1997) in Progress in Cell Cycle Research, vol. 3 (Meijier,
L. G. S. and Philippe, M., eds.), pp. 157–169, Plenum Press, New York
3 Gran4 a, X. and Reddy, E. P. (1995) Oncogene 11, 211–219
4 Ikeda, M., Jakoi, L. and Nevins, J. R. (1996) Proc. Natl. Acad. Sci. U.S.A. 93,
3215–3220
5 Cobrinik, D., Whyte, P., Peeper, D. S., Jacks, T. and Weinberg, R. A. (1993) Genes
Dev. 7, 2392–2404
6 Smith, E. J., Leone, G., Degregori, J., Jakoi, L. and Nevins, J. R. (1996) Mol. Cell.
Biol. 16, 6965–6976
7 Johnson, D. G. (1995) Oncogene 11, 1685–1692
8 Wolf, D. A., Hermeking, H., Albert, T., Herzinger, T., Kind, P. and Eick, D. (1995)
Oncogene 10, 2067–2078
9 Vairo, G., Livingston, D. M. and Ginsberg, D. (1995) Genes Dev. 9, 869–881
10 Moberg, K., Starz, M. A. and Lees, J. A. (1996) Mol. Cell. Biol. 16, 1436–1449
11 Shin, E. K., Shin, A., Paulding, C., Schaffhausen, B. and Yee, A. S. (1995) Mol. Cell.
Biol. 15, 2252–2262
12 Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J.,
Beach, D. and Lassar, A. B. (1995) Science 267, 1018–1021
13 Corbeil, H. B., Whyte, P. and Branton, P. E. (1995) Oncogene 11, 909–920
14 Kiess, M., Gill, R. M. and Hamel, P. A. (1995) Cell Growth Differ. 6, 1287–1298
15 Jiang, H. P., Lin, J., Young, S. M., Goldstein, N. I., Waxman, S., Davila, V.,
Chellappan, S. P. and Fisher, P. B. (1995) Oncogene 11, 1179–1189
16 Mayol, X., Garriga, J. and Gran4 a, X. (1996) Oncogene 13, 237–246
17 Mayol, X., Garriga, J. and Gran4 a, X. (1995) Oncogene 11, 801–808
18 Peterson, C. A., Gordon, H., Hall, Z. W., Paterson, B. M. and Blau, H. M. (1990) Cell
62, 493–502
19 Patel, G., Kreider, B., Rovera, G. and Reddy, E. P. (1993) Mol. Cell. Biol. 13,
2269–2276
20 Pickering, J. G., Weir, L., Rosenfield, K., Stetz, J., Jekanowski, J. and Isner, J. M.
(1992) J. Am. Coll. Cardiol. 20, 1430–1439
21 Wei, G. L., Krasinski, K., Kearney, M., Isner, J. M., Walsh, K. and Andres, V. (1997)
Circ. Res. 80, 418–426
22 Schreiber, E., Matthias, P., Muller, M. M. and Schaffner, W. (1989) Nucleic Acids
Res. 17, 6419
23 Fattaey, A. R., Harlow, E. and Helin, K. (1993) Mol. Cell. Biol. 13, 7267–7277
24 Hattori, M., Tugores, A., Veloz, L., Karin, M. and Brenner, D. A. (1990) DNA Cell.
Biol. 9, 777–781
25 Albrecht, J. H., Hu, M. Y. and Cerra, F. B. (1995) Biochem. Biophys. Res. Commun.
209, 648–655
26 Clowes, A. W., Reidy, M. A. and Clowes, M. M. (1983) Lab. Invest. 49, 327–333
27 Garriga, J., Mayol, X. and Gran4 a, X. (1996) Biochem. J. 319, 293–298
28 Cleaver, J. (1967) in Frontiers in Biology, vol. 6 (Neuberger, A. and Tatum, E., eds.),
pp. 184–233, North-Holland, Amsterdam/John Wiley, New York
29 Andres, V. and Walsh, K. (1996) J. Cell Biol. 132, 657–666
30 Valtieri, M., Tweardy, D. J., Caracciolo, D., Johnson, K., Mavilio, F., Altmann, S.,
Santoli, D. and Rovera, G. (1987) J. Immunol. 138, 3829–3835
31 Beijersbergen, R. L., Carlee, L., Kerkhoven, R. M. and Bernards, R. (1995) Genes
Dev. 9, 1340–1353
32 Albrecht, J., Poon, R. Y. C., Ahonen, C., Rieland, B., Deng, C. and Crary, G. (1998)
Oncogene 16, in the press
33 Albrecht, J. H., Hoffman, J. S., Kren, B. T. and Steer, C. J. (1994) FEBS Lett. 347,
157–162
34 Steer, C. J. (1995) FASEB J. 9, 1396–1400
35 Fabrikant, J. I. (1968) J. Cell Biol. 36, 551–565
654 J. Garriga and others
36 Owens, G. K. (1995) Physiol. Rev. 75, 487–517
37 Schwartz, S. M., deBlois, D. and O’Brien, E. R. (1995) Circ. Res. 77, 445–465
38 Schwartz, R. S. (1994) Lab. Invest. 71, 789–791
39 Richon, V. M., Lyle, R. E. and McGehee, R. E. (1997) J. Biol. Chem. 272,
10117–10124
40 Hateboer, G., Kerkhoven, R. M., Shvarts, A., Bernards, R. and Beijersbergen, R. L.
(1996) Genes Dev. 10, 2960–2970
Received 11 March 1998 ; accepted 28 April 1998
41 Tommasi, S. and Pfeifer, G. P. (1995) Mol. Cell. Biol. 15, 6901–6913
42 Lam, E. W. and Watson, R. J. (1993) EMBO J. 12, 2705–2713
43 Ohtani, K., Degregori, J., Leone, G., Herendeen, D. R., Kelly, T. J. and Nevins, J. R.
(1996) Mol. Cell. Biol. 16, 6977–6984
44 Zhu, L., Zhu, L., Xie, E. and Chang, L. S. (1995) Mol. Cell. Biol. 15, 3552–3562
45 Williams, C. D., Linch, D. C., Sorensen, T. S., Lathangue, N. B. and Thomas, N. S. B.
(1997) Br. J. Haematol. 96, 688–696
